John Haslam is the President and Founder of HEARD Consulting International, specializing in assisting companies with Rare Disease Medicines build winning go to market strategies in order to bring their innovation to Canadian patients. As Canadian General Manager, John built and led the Canadian operations for 2 major Rare Disease companies (Alexion & Horizon Therapeutics) over the past 12 years generating combined annual sales of $150M annually. Prior to that John worked in senior commercial roles at major pharmaceutical organizations within the industry including Bayer, Roche and Biogen. John obtained his B.Sc. in Microbiology from University of Toronto and his M.B.A. from McMaster DeGroote School of Business. John is a Board Member of Life Sciences Ontario, founding member of the Rare Innovators group and past Board Member for Innovative Medicines Canada and Biotech Canada. John has been honoured with the Canadian Organization for Rare Disorders (CORD) corporate partner award and was inducted into the Canadian Pharmaceutical Marketing Hall of Fame in October of 2015.